Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overpriced on P/F
Target Price
The average target price of CDNA is 25 and suggests 53% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell